Close
  • Latest News
  • Artificial Intelligence
  • Video
  • Big Data and Analytics
  • Cloud
  • Networking
  • Cybersecurity
  • Applications
  • IT Management
  • Storage
  • Sponsored
  • Mobile
  • Small Business
  • Development
  • Database
  • Servers
  • Android
  • Apple
  • Innovation
  • Blogs
  • PC Hardware
  • Reviews
  • Search Engines
  • Virtualization
Read Down
Sign in
Close
Welcome!Log into your account
Forgot your password?
Read Down
Password recovery
Recover your password
Close
Search
Logo
Subscribe
Logo
  • Latest News
  • Artificial Intelligence
  • Video
  • Big Data and Analytics
  • Cloud
  • Networking
  • Cybersecurity
  • Applications
  • IT Management
  • Storage
  • Sponsored
  • Mobile
  • Small Business
  • Development
  • Database
  • Servers
  • Android
  • Apple
  • Innovation
  • Blogs
  • PC Hardware
  • Reviews
  • Search Engines
  • Virtualization
More
    Subscribe
    Home Latest News

      Timing Favors Stem Cell Supporters

      Written by

      Chris Nolan
      Published August 12, 2005
      Share
      Facebook
      Twitter
      Linkedin

        eWEEK content and product recommendations are editorially independent. We may make money when you click on links to our partners. Learn More.

        When Congress returns from its August recess, the Senate hearings on the nomination of Judge John G. Roberts to the Supreme Court will be the most-watched event. Lobbyists for a wide variety of groups have already started warming up their arguments, rallying supporters and raising money.

        But another event in the U.S. Senate is going to be important and, like the Roberts nomination, could well turn into a show-down as Republicans try to sort out their position on the cutting-edge science of embryonic stem cell research.

        With some drama, U.S. Senate Majority Leader Bill Frist (R-Tenn.) announced last month that he is willing to support the stem cell legislation in the Senate thats similar to whats been approved by the U.S. House.

        This announcement, which was a break with the White House, means the legislation has a good chance of passing the Senate. President Bush, however, has said he will veto any such bill. And it is unlikely—for now—that there are enough votes in the House to override that veto.

        Frists change of heart is a good example of how things might change in Congress. In some respect, Frist is playing catch-up with his announcement of support for stem cell research legislation. The margins vary but polls show that voters favor either state-sponsored programs or the use of federal dollars to do such research.

        Republicans are less favorably inclined, but Democrats and independents—those are folks who could vote for either party—say the legislation is a good idea.

        Thats borne out at the state level. Since Californian voted to approve a $3 billion bond issue to fund embryonic stem cell research in the state, others have followed. New Jersey ($150 million), Connecticut ($100 million) and Illinois ($10 million) have all approved funding for such research. Its no coincidence that each of those states has large research facilities—Princeton University (New Jersey), Yale (Connecticut) and the University of Chicago (Illinois) —within in the borders.

        For most of these states, the related fruits of research —the discoveries, intellectual property and ancillary benefits—are as important as the research itself. Embryonic stem cells may indeed hold the keys to cures for diseases like Parkinsons, diabetes and cancers, but the discoveries scientist make as they do that research and those experiments are often as important as the “assigned” work.

        That makes stem cell research an economic issue as much as anything else. Thats not an argument you hear made in political circles, however. And its one that President Bush has not addressed in his decision to ban all research using human embryos. Nor have many of the legislations proponents—outside California—made this argument.

        /zimages/2/28571.gifRoberts nomination highlights Webs influence. Click here to read more.

        Instead the debate has been one over when and how life begins. Which takes us back to the U.S. Senate and Roberts. Much of the debate over his suitability for the Supreme Court will center on his approach toward a number of social issues, among them abortion. This is where Roberts nomination and stem cells intersect.

        The debate over Roberts suitability for the Supreme Court is in the hands of someone who cares very much about federal funding for stem cell research: Sen. Arlen Specter, who is well-known for his independent points of view on a number of issues as well as his willingness to speak out—sometimes harshly against those who oppose him.

        Specter, a Republican from Pennsylvania, is ill with cancer and, in part because of the research he believes would be possible, has sponsored legislation to give federal funds to embryonic stem cell research. Specter—who has lost his hair from the chemotherapy—is also in charge of the Roberts hearings.

        He couldnt ask for a better platform to air his views than the sometimes free-ranging Senate confirmation hearings and press conferences that accompany them.

        Does that mean stem cell legislation is now a slam-dunk for passage? No. But it does take a program that enjoys support from voters and places it front and center before the public in a unique and dramatic way. That puts pressure on the White House and on Congress at a less-than-opportune moment: As it face the beginnings of the 2006 election cycle.

        eWEEK.com technology and politics columnist Chris Nolan spent years chronicling the excesses of the dot-com era with incisive analysis leavened with a dash of humor. Before that, she covered politics and technology in D.C. You can read her musings on politics and technology every day in her Politics from Left to Right Weblog. She can be reached at [email protected].

        /zimages/2/28571.gifCheck out eWEEK.coms for the latest news, views and analysis of technologys impact on government and politics.

        Chris Nolan
        Chris Nolan
        Nolan's work is well-known to tech-savvy readers. Her weekly syndicated column, 'Talk is Cheap,' appeared in The New York Post, Upside, Wired.com and other publications. Debuting in 1997 at the beginnings of the Internet stock boom, it covered a wide variety of topics and was well regarded for its humor, insight and news value.Nolan has led her peers in breaking important stories. Her reporting on Silicon Valley banker Frank Quattrone was the first to uncover the now infamous 'friend of Frank' accounts and led, eventually, to Quattrone's conviction on obstruction of justice charges.In addition to columns and Weblogging, Nolan's work has appeared in The Washington Post, The New Republic, Fortune, Business 2.0 and Condé, Nast Traveler, and she has spoken frequently on the impact of Weblogging on politics and journalism.Before moving to San Francisco, Nolan, who has more than 20 years of reporting experience, wrote about politics and technology in Washington, D.C., for a series of television trade magazines. She holds a B.A. from Barnard College, Columbia University.

        Get the Free Newsletter!

        Subscribe to Daily Tech Insider for top news, trends & analysis

        Get the Free Newsletter!

        Subscribe to Daily Tech Insider for top news, trends & analysis

        MOST POPULAR ARTICLES

        Artificial Intelligence

        9 Best AI 3D Generators You Need...

        Sam Rinko - June 25, 2024 0
        AI 3D Generators are powerful tools for many different industries. Discover the best AI 3D Generators, and learn which is best for your specific use case.
        Read more
        Cloud

        RingCentral Expands Its Collaboration Platform

        Zeus Kerravala - November 22, 2023 0
        RingCentral adds AI-enabled contact center and hybrid event products to its suite of collaboration services.
        Read more
        Artificial Intelligence

        8 Best AI Data Analytics Software &...

        Aminu Abdullahi - January 18, 2024 0
        Learn the top AI data analytics software to use. Compare AI data analytics solutions & features to make the best choice for your business.
        Read more
        Latest News

        Zeus Kerravala on Networking: Multicloud, 5G, and...

        James Maguire - December 16, 2022 0
        I spoke with Zeus Kerravala, industry analyst at ZK Research, about the rapid changes in enterprise networking, as tech advances and digital transformation prompt...
        Read more
        Video

        Datadog President Amit Agarwal on Trends in...

        James Maguire - November 11, 2022 0
        I spoke with Amit Agarwal, President of Datadog, about infrastructure observability, from current trends to key challenges to the future of this rapidly growing...
        Read more
        Logo

        eWeek has the latest technology news and analysis, buying guides, and product reviews for IT professionals and technology buyers. The site’s focus is on innovative solutions and covering in-depth technical content. eWeek stays on the cutting edge of technology news and IT trends through interviews and expert analysis. Gain insight from top innovators and thought leaders in the fields of IT, business, enterprise software, startups, and more.

        Facebook
        Linkedin
        RSS
        Twitter
        Youtube

        Advertisers

        Advertise with TechnologyAdvice on eWeek and our other IT-focused platforms.

        Advertise with Us

        Menu

        • About eWeek
        • Subscribe to our Newsletter
        • Latest News

        Our Brands

        • Privacy Policy
        • Terms
        • About
        • Contact
        • Advertise
        • Sitemap
        • California – Do Not Sell My Information

        Property of TechnologyAdvice.
        © 2024 TechnologyAdvice. All Rights Reserved

        Advertiser Disclosure: Some of the products that appear on this site are from companies from which TechnologyAdvice receives compensation. This compensation may impact how and where products appear on this site including, for example, the order in which they appear. TechnologyAdvice does not include all companies or all types of products available in the marketplace.